To estimate the improvement in the prediction of mortality and readmission for both types of cTn (cTnI Sgx and cTnI-Ultra), a clinical model comprising age, sex, history of myocardial infarction, heart failure, hypertension, diabetes, atrial fibrillation, and kidney disease was designed, and its calibration and discrimination capacity were analysed using the C-index (Table 4) before and after adding both types of cTnI to the clinical model (Models A and B, respectively). This evidence concerns the gene TNNI3 and myocardial infarction.